NTLA250117C20000
- 0.03
- -0.07-70.00%
Intellia Therapeutics Newsroom
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Analyst Ratings
BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50
Intellia Therapeutics (NTLA) Receives a Buy From Evercore ISI
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $60
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $29
Strategic Realignment and Pipeline Potential Drive Buy Rating for Intellia Therapeutics
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $47
RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $50
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90
Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Price Target Maintained With a $14.00/Share by Wedbush
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91